Statistical Significance Does Not Prove Clinical Relevance, FDA Says
Executive Summary
Having statistically significant trial results does not mean they are clinically meaningful
You may also be interested in...
FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee
FDA's Pazdur says the time has come for an Oncologic Drugs Advisory Committee meeting devoted to issues surrounding use of progression-free survival endpoints - including clinical relevance.
FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee
FDA Office of Oncology Drug Products Director Richard Pazdur plans to convene an advisory committee meeting to clarify standards for use of progression-free survival data, a move prompted by industry's aggressive adoption of the surrogate endpoint and, more broadly, the gradual decline in the level of drug benefit that sponsors seek to use in support of a cancer drug approval
FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee
FDA Office of Oncology Drug Products Director Richard Pazdur plans to convene an advisory committee meeting to clarify standards for use of progression-free survival data, a move prompted by industry's aggressive adoption of the surrogate endpoint and, more broadly, the gradual decline in the level of drug benefit that sponsors seek to use in support of a cancer drug approval